1. Home
  2. ISPC vs ENSC Comparison

ISPC vs ENSC Comparison

Compare ISPC & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo iSpecimen Inc.

ISPC

iSpecimen Inc.

HOLD

Current Price

$0.37

Market Cap

5.7M

Sector

Health Care

ML Signal

HOLD

Logo Ensysce Biosciences Inc.

ENSC

Ensysce Biosciences Inc.

HOLD

Current Price

$1.09

Market Cap

6.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ISPC
ENSC
Founded
2009
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Precision Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.7M
6.3M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
ISPC
ENSC
Price
$0.37
$1.09
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
541.1K
418.0K
Earning Date
11-17-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,352,744.00
$4,487,973.00
Revenue This Year
$35.93
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
1.51
52 Week Low
$0.36
$1.08
52 Week High
$3.38
$9.88

Technical Indicators

Market Signals
Indicator
ISPC
ENSC
Relative Strength Index (RSI) 31.06 27.48
Support Level $0.36 $1.08
Resistance Level $0.44 $1.24
Average True Range (ATR) 0.04 0.13
MACD 0.00 -0.01
Stochastic Oscillator 6.47 1.75

Price Performance

Historical Comparison
ISPC
ENSC

About ISPC iSpecimen Inc.

iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.

About ENSC Ensysce Biosciences Inc.

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

Share on Social Networks: